ArticleTherapeutic advances in medical oncology2023
Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.
Article in Therapeutic advances in medical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Prognostic value of systemic immune-inflammation index for colorectal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Prognostic value and clinicopathological significance of pre-and post-treatment systemic immune-inflammation index in colorectal cancer patients: a meta-analysis.World journal of surgical oncology · 2025Pooled it
- Prognostic value of platelet to lymphocyte ratio in patients with colorectal cancer undergoing chemotherapy: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Inflammation and Colorectal Cancer: A Meta-Analysis of the Prognostic Significance of the Systemic Immune-Inflammation Index (SII) and the Systemic Inflammation Response Index (SIRI).International journal of molecular sciences · 2024Pooled it
- Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group (TOG) Study.International journal of cancer · 2026Article
- Article
- Modified Aarhus Composite Biomarker Score as a New Risk-Stratification Tool in Metastatic Colorectal Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Serial assessment of inflammatory biomarkers as a prognostic factor for first-line treatment outcomes in patients with metastatic colorectal cancer: single-center retrospective study.Frontiers in oncology · 2026Article
- Association of immuno-inflammatory biomarkers with response to neoadjuvant chemotherapy and prognosis in HER2-positive breast cancer: dual-center clinical evidence.Frontiers in immunology · 2026Article
- Development and validation of an AI-augmented deep learning model for survival prediction in de novo metastatic colorectal cancer.Discover oncology · 2025Article
- Systemic Immune-Inflammation Index as a Predictor of Progression in Melanoma: A Retrospective Cohort Study.Cureus · 2025Article
- Combined preoperative platelet-albumin ratio and cancer inflammation prognostic index predicts prognosis in colorectal cancer: a retrospective study.Scientific reports · 2025Article
- Are Calculated Immune Markers with or Without Comorbidities Good Predictors of Colorectal Cancer Survival? The Results of a Longitudinal Study.Medical sciences (Basel, Switzerland) · 2025Observational
- Association of the systemic immune-inflammatory index and systemic inflammatory response index with all-cause and cardiovascular mortality in individuals with metabolic inflammatory syndrome.European journal of medical research · 2025Article
- Integrated singlecell and bulk RNA-seq analysis identifies a prognostic signature related to inflammation in colorectal cancer.Scientific reports · 2025Article
- NOS2/ARG1 axis and immune cell ratios as promising prognostic and predictive biomarkers for Cetuximab combined with chemotherapy in wt-KRAS human colorectal cancer.Frontiers in immunology · 2025Article
- Relationship between systemic immune-inflammation index and long-term all-cause and cause-specific mortality among adult asthma patients: a population-based study.BMC pulmonary medicine · 2024Article
- Association of the systemic immune-inflammation index with all-cause and cardiovascular mortality in individuals with rheumatoid arthritis.Scientific reports · 2024Article
- Article
- The Predictive Value of Systemic Inflammatory Biomarkers in Predicting Postoperative Systemic Inflammatory Response Syndrome After Percutaneous Nephrolithotomy.International journal of general medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Validated predictors of sensitivity or resistance to Bevacizumab (Bev) are not available, and Inflammatory Indexes (IIs) has been reported to be useful prognostic factors in various malignant solid tumours, including metastatic colorectal cancer (mCRC). Objectives: To explore the prognostic value of IIs in mCRC patients treated with first-line chemotherapy plus Bev. Design: One hundred and eighty-two patients diagnosed with mCRC and treated with first line chemotherapy plus Bev were considered for this prospective non-pharmacological study. Neutrophil, lymphocyte, platelet, aspartate transaminase (AST) and lactate dehydrogenase (LDH) tests were carried out at baseline and before each treatment cycle, according to clinical practice. Methods: Pre-treatment Systemic Immune-inflammation Index (SII), Colon Inflammatory Index (CII) and Aspartate aminotransferase-Lymphocyte Ratio Index (ALRI) were evaluated to assess a correlation with progression-free survival (PFS) and overall survival (OS). Results: In the overall population, PFS and OS were lower in patients with high SII (HR 1.64, Conclusion: Our results demonstrate and confirm that IIs, and in particular SII and ALRI, are easy to measure prognostic markers for patient candidates to first line chemotherapy plus Bev for mCRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.